Recently, BioRuler Biotech announced the completion of a Series A financing round exceeding RMB 100 million. The round was led by a prominent biopharmaceutical investment firm, with continued participation from several existing investors. The proceeds will be primarily allocated to advancing clinical validation of its core cancer early detection products, optimizing its technology platform, and expanding commercialization efforts. Founded in 2020, BioRuler focuses on developing liquid biopsy technologies based on multi-omics and artificial intelligence, aiming to deliver non-invasive, highly sensitive, and specific solutions for early cancer screening. The company has built an innovative multi-dimensional platform integrating cfDNA methylation, fragmentomics, and protein biomarkers, demonstrating strong performance in detecting high-incidence cancers such as colorectal and liver cancer. This funding round underscores strong investor confidence in BioRuler’s technological approach and product potential, providing critical support for accelerating regulatory approvals and market expansion. Looking ahead, the company plans to extend its focus to pan-cancer early detection and drive its diagnostic assays into routine clinical use, contributing to the broader goal of ‘early detection, early intervention, and early cure’ in cancer management.
近日，博瑞策生物宣布完成超1亿元人民币的A轮融资。本轮融资由知名生物医药投资机构领投，多家老股东持续跟投，资金将主要用于推进其核心肿瘤早筛产品的临床验证、技术平台优化及商业化布局。博瑞策生物成立于2020年，专注于基于多组学和人工智能的液体活检技术研发，致力于为癌症早期筛查提供高灵敏度、高特异性的无创检测解决方案。公司已构建覆盖cfDNA甲基化、片段组学及蛋白质标志物等多维度的创新技术平台，并在结直肠癌、肝癌等多个高发癌种中展现出优异的检测性能。此次融资不仅体现了资本市场对博瑞策技术路径和产品前景的高度认可，也为其加速产品注册审批、拓展市场渠道提供了有力支撑。未来，公司计划进一步拓展至泛癌种早筛领域，并推动其检测产品进入临床常规应用，助力实现‘早发现、早干预、早治愈’的癌症防控目标。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/6947.html